For the first time, Medicare is paying for the blockbuster obesity drugs Wegovy and Zepbound, and the sticker shock that kept them out of reach for older Americans has been replaced by a flat $50 monthly copay. The change arrived through a federal demonstration that quietly took effect this summer, converting medications that once listed above $1,000 a month into a predictable pharmacy charge. The catch is that this coverage is a time-limited pilot, not a permanent benefit, and it runs on a separate track from the Part D drug plans most beneficiaries already carry.
How the Medicare GLP-1 Bridge charges $50 a month
The coverage flows through a program called the Medicare GLP-1 Bridge, a demonstration run by the Centers for Medicare and Medicaid Services. It began on July 1, 2026 and is scheduled to continue through December 31, 2027, giving eligible enrollees a fixed price on drugs that were previously excluded from Medicare when prescribed for weight loss alone.
Under the Bridge, a qualifying beneficiary pays $50 for each 30-day supply of a covered medication, and that copay does not climb as a patient moves to a higher dose. The covered list includes Novo Nordisk’s Wegovy, in both its injectable and oral forms, Eli Lilly’s Zepbound KwikPen, and Lilly’s oral obesity pill sold as Foundayo. For a class of drugs whose cash prices routinely topped $1,000 a month, a capped $50 charge represents a shift measured in thousands of dollars a year.
The demonstration also operates differently from ordinary drug coverage. Although enrollees must be signed up for a Part D plan to take part, the Bridge sits outside the standard Part D benefit, with prescriptions and prior-authorization requests routed to a central processor that CMS manages rather than to each individual plan. That structure lets the government set one national copay instead of leaving the price to hundreds of separate plan formularies.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
The price deal that made $50 possible
The low copay did not appear on its own. It rests on most-favored-nation pricing agreements the Trump administration reached with the two drugmakers that dominate the market, an arrangement announced in late 2025 and aimed at pulling U.S. prices closer to what other wealthy countries pay. Those deals set a far lower baseline that the Medicare demonstration could then build on.
As part of the arrangement, Lilly and Novo Nordisk agreed to a monthly net price near $245 for their injectable GLP-1 products sold to Medicare and Medicaid, a figure that news coverage described as roughly a 75% cut from prevailing list prices. The same agreements route discounted cash prices to consumers through a federal purchasing site, and they tie the companies to large domestic manufacturing commitments.
Federal pharmacy analysts framed the agreements as a policy pivot rather than a one-off discount. An industry update on the deal noted that the reduced prices were the lever that opened the door to Medicare coverage for obesity, a use the program had refused to pay for since its inception. Reporting on the original announcement said the manufacturers accepted the lower prices in exchange for coverage volume and other trade concessions, a trade-off detailed when the deal was unveiled.
Who qualifies, and what the pilot leaves unsettled
Eligibility is tied to weight and health status, not to a diagnosis alone. According to the program’s terms, a beneficiary generally needs a body mass index of 35 or higher, or a body mass index of 27 or higher combined with other clinical criteria, to enter the Bridge. That threshold sets the drugs apart from earlier Medicare coverage, which paid for these same medications only when they treated conditions such as diabetes or reduced cardiovascular risk, never obesity by itself.
The temporary nature of the demonstration is its most important limitation. Because the Bridge is written to expire at the end of 2027, the current $50 copay carries no guarantee beyond that date, and CMS has already delayed a separate, broader model that was meant to fold GLP-1 coverage into Part D on a more permanent footing. A beneficiary who starts a drug now faces uncertainty about what the medication will cost once the pilot lapses.
That uncertainty matters because obesity medications are typically taken indefinitely, and stopping them often reverses the weight loss they produce. A patient who builds a treatment plan around a $50 copay is exposed if the demonstration ends without a successor program in place, since the drugs could revert to prices set by ordinary plan formularies or by cash-pay lists.
For now, the practical picture is straightforward: enrollees who meet the criteria and are willing to work through the central prior-authorization process can obtain drugs that were financially out of reach a year ago. The harder question is whether a coverage change delivered as a two-year experiment becomes a lasting part of Medicare, or whether the $50 price proves to be a window that closes on schedule at the end of 2027.
This article was researched and drafted with the assistance of artificial intelligence.
More Financial Reading
